US DoJ Argues Against Patenting Isolated Genes, But USPTO Will Maintain Status Quo

In a filing with the federal appeals court, the DoJ attempted to strike a balance between rewarding inventions that result from genomic discoveries and ensuring that discoveries of natural phenomena remain in the "storehouse of knowledge of all men." Meanwhile, it's business as usual at the USPTO until the appeals court rules on Myriad's challenged BRCA patents.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.